MCID: CHR043
MIFTS: 36

Chronic Inflammatory Demyelinating Polyneuritis

Categories: Neuronal diseases

Aliases & Classifications for Chronic Inflammatory Demyelinating Polyneuritis

MalaCards integrated aliases for Chronic Inflammatory Demyelinating Polyneuritis:

Name: Chronic Inflammatory Demyelinating Polyneuritis 12 15
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating 44 70

Classifications:



External Ids:

Disease Ontology 12 DOID:2536
ICD9CM 34 357.81
MeSH 44 D020277
NCIt 50 C84636
SNOMED-CT 67 128209004
ICD10 32 G61.81
UMLS 70 C0393819

Summaries for Chronic Inflammatory Demyelinating Polyneuritis

MalaCards based summary : Chronic Inflammatory Demyelinating Polyneuritis, also known as polyradiculoneuropathy, chronic inflammatory demyelinating, is related to chronic inflammatory demyelinating polyradiculoneuropathy and immunodeficiency 65. An important gene associated with Chronic Inflammatory Demyelinating Polyneuritis is HEXA (Hexosaminidase Subunit Alpha), and among its related pathways/superpathways are PEDF Induced Signaling and Akt Signaling. The drugs Glycine and Immunologic Factors have been mentioned in the context of this disorder. Affiliated tissues include skin, lymph node and eye, and related phenotypes are hematopoietic system and homeostasis/metabolism

Related Diseases for Chronic Inflammatory Demyelinating Polyneuritis

Diseases related to Chronic Inflammatory Demyelinating Polyneuritis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 176)
# Related Disease Score Top Affiliating Genes
1 chronic inflammatory demyelinating polyradiculoneuropathy 11.6
2 immunodeficiency 65 10.4 PRF1 FASLG
3 necrotic uveal melanoma 10.3 IFNG CD8A
4 spinal muscular atrophy type 0 10.3 SMN2 SMN1
5 lymphocytic gastritis 10.3 FASLG CD8A
6 nephrolithiasis/osteoporosis, hypophosphatemic, 2 10.2 SMN2 SMN1 HEXA
7 anterior horn cell disease 10.2 SMN2 SMN1 HEXA
8 staphylococcal toxic shock syndrome 10.2 TNF IFNG
9 autoimmune myocarditis 10.2 TNF IFNG
10 spotted fever rickettsiosis 10.2 TNF IFNG
11 polyarticular juvenile idiopathic arthritis 10.2 TNF IFNG
12 chediak-higashi syndrome 10.2 PRF1 FASLG CD8A
13 skeletal tuberculosis 10.2 TNF IFNG
14 systemic onset juvenile idiopathic arthritis 10.2 TNF PRF1
15 tay-sachs disease 10.2 SMN2 SMN1 HEXA
16 marburg hemorrhagic fever 10.2 CD8A CCL4L1
17 chronic beryllium disease 10.2 TNF IFNG
18 progressive muscular atrophy 10.2 TRPV4 SMN2 SMN1
19 opportunistic bacterial infectious disease 10.1 TNF IFNG
20 toxicodendron dermatitis 10.1 TNF CD8A
21 type 1 diabetes mellitus 23 10.1 TNF CD8A
22 nocardiosis 10.1 TNF IFNG
23 soft tissue sarcoma 10.1 TNF IFNG
24 acute graft versus host disease 10.1 TNF IFNG FASLG
25 gastrointestinal tuberculosis 10.1 TNF IFNG
26 lethal midline granuloma 10.1 PRF1 CD2
27 erythema multiforme 10.1 TNF IFNG FASLG
28 listeria meningitis 10.1 TNF CD8A
29 graft-versus-host disease 10.1 TNF IFNG FASLG
30 tertiary syphilis 10.1 TNF CD8A
31 paine syndrome 10.1 TRPV4 TNF KNG1
32 lymphadenitis 10.1 TNF IFNG FASLG
33 smallpox 10.1 TNF IL18R1 IFNG
34 thyroiditis 10.1 TNF IFNG FASLG
35 nasal cavity lymphoma 10.1 PRF1 CD2
36 listeriosis 10.1 TNF PRF1 CD8A
37 cerebritis 10.1 TNF CD8A
38 spinal muscular atrophy, x-linked 2 10.1 SMN2 SMN1
39 parapsoriasis 10.1 CD8A CD2
40 granulomatous hepatitis 10.1 TNF CD8A
41 skin sarcoidosis 10.1 TNF IFNG CD8A
42 uveoparotid fever 10.1 TNF IFNG CD8A
43 scleral disease 10.1 TNF IFNG CD8A
44 purpura 10.1 TNF MPL IFNG
45 miliary tuberculosis 10.1 TNF IFNG CD8A
46 mucocutaneous leishmaniasis 10.1 TNF IFNG CD8A
47 rubella 10.1 TNF IL18R1 IFNG
48 chorioretinitis 10.0 TNF IFNG CD8A
49 fungal meningitis 10.0 TNF IFNG CD8A
50 macs syndrome 10.0 TNF IFNG CD8A

Graphical network of the top 20 diseases related to Chronic Inflammatory Demyelinating Polyneuritis:



Diseases related to Chronic Inflammatory Demyelinating Polyneuritis

Symptoms & Phenotypes for Chronic Inflammatory Demyelinating Polyneuritis

MGI Mouse Phenotypes related to Chronic Inflammatory Demyelinating Polyneuritis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.03 CCL11 CD8A FASLG FUT4 IFNG IL17F
2 homeostasis/metabolism MP:0005376 9.97 FASLG FUT4 HEXA IFNG IL18R1 IL9
3 immune system MP:0005387 9.73 CCL11 CD8A FASLG FUT4 IFNG IL17F
4 normal MP:0002873 9.28 CCL11 CD2 CD8A FASLG IFNG IL17F

Drugs & Therapeutics for Chronic Inflammatory Demyelinating Polyneuritis

Drugs for Chronic Inflammatory Demyelinating Polyneuritis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 62)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Glycine Approved, Nutraceutical, Vet_approved Phase 3 56-40-6 750
2 Immunologic Factors Phase 3
3 Immunoglobulins Phase 3
4 Antibodies Phase 3
5 Fingolimod Hydrochloride Phase 3
6 Immunoglobulins, Intravenous Phase 3
7 Rho(D) Immune Globulin Phase 3
8 gamma-Globulins Phase 3
9 Pharmaceutical Solutions Phase 2, Phase 3
10
Interferon beta-1a Approved, Investigational Phase 2 145258-61-3 6438354
11
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
12
Carmustine Approved, Investigational Phase 2 154-93-8 2578
13
Mechlorethamine Approved, Investigational Phase 2 51-75-2 4033
14
Cytarabine Approved, Investigational Phase 2 147-94-4 6253
15
Melphalan Approved Phase 2 148-82-3 4053 460612
16
Etoposide Approved Phase 2 33419-42-0 36462
17
rituximab Approved Phase 2 174722-31-7 10201696
18
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
19
Biotin Approved, Investigational, Nutraceutical Phase 2 58-85-5 171548
20
Phenylalanine Approved, Investigational, Nutraceutical Phase 2 63-91-2 6140
21
Cortisone Experimental Phase 2 53-06-5 222786
22
Rozanolixizumab Investigational Phase 2 1584645-37-3
23 Micronutrients Phase 2
24 Vitamin B9 Phase 2
25 Trace Elements Phase 2
26 Nutrients Phase 2
27 Antioxidants Phase 2
28 Vitamin B Complex Phase 2
29 Folate Phase 2
30 Protective Agents Phase 2
31 Alpha-lipoic Acid Phase 2
32 Vitamins Phase 2
33 Thioctic Acid Phase 2
34 Vitamin B7 Phase 2
35 Adjuvants, Immunologic Phase 2
36 Interferon-beta Phase 2
37 interferons Phase 2
38 Hormones Phase 2
39 Hormone Antagonists Phase 2
40 glucocorticoids Phase 2
41 Antineoplastic Agents, Hormonal Phase 2
42 Anti-Inflammatory Agents Phase 2
43 Anti-Infective Agents Phase 2
44 Tubulin Modulators Phase 2
45 Etoposide phosphate Phase 2
46 Antimitotic Agents Phase 2
47 Antilymphocyte Serum Phase 2
48 Dermatologic Agents Phase 2
49 Antimetabolites Phase 2
50 Antiviral Agents Phase 2

Interventional clinical trials:

(show top 50) (show all 63)
# Name Status NCT ID Phase Drugs
1 Treatment With Gamunex 10% Intravenous Immunoglobulin (IVIg) for Patients With Demyelination and Diabetes Mellitus: A Blinded, Placebo-Controlled Crossover Pilot Study Unknown status NCT02372149 Phase 4 10% intravenous immunoglobulin (IVIg);0.9% sodium chloride
2 Randomized Study of Single vs. Multiple Privigen Dose Regimens in Pediatric CIDP Recruiting NCT03684018 Phase 4
3 Randomized, Parallel Study of Subcutaneous Versus Intravenous Immunoglobulin in Treatment-naïve Patients With Chronic Inflammatory Demyelinating Polyneuropathy Recruiting NCT04589299 Phase 4
4 An Open-Label Trial of Alemtuzumab in Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIPD) Withdrawn NCT01757574 Phase 4 Alemtuzumab infusion
5 Prospective, Open-Label, Phase IIIb Study Evaluating the Safety, Tolerability and Efficacy of Panzyga® in Patients With Chronic Inflammatory Demyelinating Polyneuropathy Administered at Standard and High Infusion Rates Unknown status NCT03166527 Phase 3 Immune Globulin 10% Intravenous Solution
6 Phase III Multicenter Double Blind Controlled Trial of Human Immune Globulin Therapy in Previously Untreated Patients With Chronic Inflammatory Demyelinating Neuropathy Completed NCT00004286 Phase 3 immune globulin
7 Multicenter, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety of IGIV-Chromatography (IGIV-C), 10% Treatment in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy Completed NCT00220740 Phase 3 Immune Globulin IV (Human), 10% Caprylate/Chromatography Purified;Albumin (Human) 25%, United States Pharmacopeia (USP)
8 Phase III Randomized, Double-Blind, Placebo-Controlled Study of 3,4-Diaminopyridine for Demyelinating Polyneuropathy Completed NCT00004939 Phase 3 ,4-diaminopyridine
9 Phase III Randomized, Double-Blind, Placebo-Controlled Study of Intravenous Immune Globulin for Chronic Inflammatory Demyelinating Polyneuropathy Completed NCT00004772 Phase 3 Immune globulin
10 A Single-arm Study to Demonstrate the Efficacy and Safety of Privigen in the Treatment of Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Completed NCT01184846 Phase 3
11 Multicentre Randomized Open-label Trial to Compare Efficacy and Tolerance of Corticosteroids and IVIg in Patients With Chronic Inflammatory Demyelinating Polyneuropathy on a One Year Follow up Completed NCT01349270 Phase 3 Immunoglobulin perfusion;Prednisone
12 Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Phase III Study to Investigate the Efficacy, Safety, and Tolerability of 2 Different Doses of IgPro20 (Subcutaneous Immunoglobulin) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - the PATH Study Completed NCT01545076 Phase 3
13 A Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Fingolimod 0.5 mg Administered Orally Once Daily Versus Placebo in Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Completed NCT01625182 Phase 3 Fingolimod;Placebo Comparator
14 An International, Multicentre, Efficacy and Safety Study of I10E in Initial and Maintenance Treatment of Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy. Completed NCT02293460 Phase 3 I10E
15 Multicenter, Open-label Extension Study to Investigate the Long-term Safety and Efficacy of IgPro20 in Maintenance Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Subjects Completing Study IgPro20_3003 Completed NCT02027701 Phase 3
16 NPB-01(Intravenous Immunoglobulin) Maintenance Therapy for Patients With Chronic Inflammatory Demyelinating Polyneuropathy. Completed NCT01824251 Phase 3 NPB-01
17 A Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Immune Globulin Infusion 10% (Human) With Recombinant Human Hyaluronidase (HYQVIA/HyQvia) and Immune Globulin Infusion (Human), 10% (GAMMAGARD LIQUID/KIOVIG) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Recruiting NCT02549170 Phase 3
18 Long-Term Tolerability and Safety of Immune Globulin Infusion 10% (Human) With Recombinant Human Hyaluronidase (HYQVIA/HyQvia) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Recruiting NCT02955355 Phase 3
19 Double-blind, Placebo-controlled, Randomised, Multicentre, Adaptive, Two-stage Phase 2/3 Study Evaluating Safety and Efficacy of Three Dosages of NewGam in CIDP Patients Terminated NCT01225276 Phase 2, Phase 3 NewGam 10%;Placebo;NewGam 10%;NewGam 10%
20 International, Multicentre, Efficacy and Safety Study of I10E in the Maintenance Treatment of Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy: Extension of PRISM Study I10E-1302" Terminated NCT02317562 Phase 3 I10E
21 Randomised, Double-blinded, Placebo-controlled Trial of Subcutaneous Immunoglobulin Treatment in Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Completed NCT01017159 Phase 2 Subcutaneous immunoglobulin
22 Lipoic Acid for Chronic Inflammatory Demyelinating Polyneuropathy-A Randomized, Double-Blind, Placebo Controlled Pilot Study Completed NCT00962429 Phase 2 lipoic acid
23 The Efficacy of High-Dose Intravenous Immunoglobulin in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Completed NCT00001287 Phase 2 intravenous immunoglobulin (IVIg)
24 SERENDEM Study: MD1003 in Patients Suffering From Demyelinating Neuropathies, an Open Label Pilot Study Completed NCT02967679 Phase 2 MD1003
25 Non-myeloablative Autologous Hematopoietic Stem Cell Transplantation in Patients With Chronic Inflammatory Demyelinating Polyneuropathy: A Phase II Trial Completed NCT00278629 Phase 2
26 A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Determine the Safety and Efficacy of AVONEX When Used in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Completed NCT00099489 Phase 2 Interferon Beta-1a
27 Open-label Extension of the ARGX-113-1802 Trial to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Recruiting NCT04280718 Phase 2
28 A Phase 2 Trial to Investigate the Efficacy, Safety, and Tolerability of Efgartigimod PH20 SC in Adult Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Recruiting NCT04281472 Phase 2
29 High-Dose Immunosuppressive Therapy Using Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) + Thymoglobulin Followed by Syngeneic or Autologous Hematopoietic Cell Transplantation for Patients With Autoimmune Neurologic Diseases Recruiting NCT00716066 Phase 2 Carmustine;Cytarabine;Etoposide;Melphalan;Prednisone
30 A Phase 2, Multicenter, Open-label, Proof-of-concept Study Evaluating the Efficacy, Safety, and Tolerability of BIVV020 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Recruiting NCT04658472 Phase 2 BIVV020
31 The Evaluation of Efficacy and Safety of Rituximab (Genetical Recombination) in Refractory Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Patients With Immunoglobulin G4 (IgG4) Autoantibodies in the Exploratory Clinical Trial Active, not recruiting NCT03864185 Phase 2
32 A Multicenter, Randomized, Subject-Blind, Investigator-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy, Safety, and Tolerability of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Active, not recruiting NCT03861481 Phase 2 Rozanolixizumab
33 An Open-Label Extension Study to Investigate the Long-Term Safety, Tolerability, and Efficacy of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Enrolling by invitation NCT04051944 Phase 2 Rozanolixizumab
34 Rituximab in Chronic Inflammatory Demyelinating Polyneuropathy: A Phase II Study Not yet recruiting NCT04480450 Phase 2 Rituximab
35 Pilot Study of Acthar® Gel in Chronic Inflammatory Demyelinating Neuropathy Withdrawn NCT02574962 Phase 2 H.P. Acthar® Gel
36 A Phase II Trial of High-dose Cyclophosphamide for Moderate to Severe Refractory Chronic Inflammatory Demyelinating Polyneuropathy Withdrawn NCT01236456 Phase 2 Cyclophosphamide
37 A PHASE 1, RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN, PLACEBO-CONTROLLED, FIRST-IN-HUMAN TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF PF-06755347 AFTER SINGLE ASCENDING INTRAVENOUS AND SUBCUTANEOUS DOSING TO HEALTHY ADULT MALE PARTICIPANTS Recruiting NCT03275740 Phase 1 PF-06755347 intravenous;Placebo intravenous;PF-06755347 subcutaneous;Placebo subcutaneous
38 sCD163 & CD19 as Candidate Biomarkers in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - A Study of sCD163 in the Cerebrospinal Fluid Unknown status NCT02271724
39 Identification of the Mechanisms of Action of Intravenous Immunoglobulins in CIDP by Analysis of the Genetic Expression Profile in Blood Mononuclear Cells Unknown status NCT02404298 IVIg
40 A Study of Subcutaneous Immunoglobulin as Chronic Treatment for Patients With Chronic Inflammatory Demyelinating Polyneuropathy Unknown status NCT02465359 Immune Globulin Subcutaneous (Human)
41 Quantification of Nerve Stiffness in Patients With Peripheral Neuropathies Unknown status NCT03397303
42 Exploratory Study of Predictive Markers of the Therapeutic Response in Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy Treated With Intravenous Immunoglobulin Unknown status NCT02892890
43 "Clinical Study of Intravenous Immunoglobulin Treatment of Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy" Completed NCT00305266 intravenous gammaglobulin
44 Intravenous Immunoglobulin (IVIg) Treatment-Related Fluctuations in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Patients Using Daily Grip Strength Measurements (GRIPPER) Completed NCT02414490 Intravenous Immunoglobulin
45 Prevalence of Decreased Corneal Sensation in Patients With Chronic Inflammatory Demyelinating Polyneuropathy Completed NCT01379833
46 MRI of the Brachial Plexus and Chronic Inflammatory Demyelinating Polyradiculoneuropathy: Assessment of DTI-derived Measurements at 3.0-T Completed NCT03460951
47 The Influence of Immunoglobulin Dosage and Administration on Development of Hemolytic Anemia and Variation on Muscle Strength in Patients With CIDP and MMN Completed NCT02111590 Immunoglobulins
48 Effect of Resistance and Aerobic Exercise on Muscle Strength, Aerobic Capacity and Quality of Life in Patients Treated With Immunoglobulin for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) or Multifocal Motor Neuropathy (MMN) Completed NCT02121678
49 Magnetic Resonance Imaging and Ultrasound Imaging of Peripheral Nerves in Patients Treated With Immunoglobulin in Chronic Inflammatory Demyelinating Polyradiculoneuropathy. Completed NCT02017769
50 Magnetic Resonance Diagnostics of Diabetic Peripheral Neuropathy Completed NCT01847937

Search NIH Clinical Center for Chronic Inflammatory Demyelinating Polyneuritis

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Immunoglobulins, Intravenous

Cochrane evidence based reviews: polyradiculoneuropathy, chronic inflammatory demyelinating

Genetic Tests for Chronic Inflammatory Demyelinating Polyneuritis

Anatomical Context for Chronic Inflammatory Demyelinating Polyneuritis

MalaCards organs/tissues related to Chronic Inflammatory Demyelinating Polyneuritis:

40
Skin, Lymph Node, Eye, Myeloid

Publications for Chronic Inflammatory Demyelinating Polyneuritis

Articles related to Chronic Inflammatory Demyelinating Polyneuritis:

# Title Authors PMID Year
1
Chronic inflammatory demyelinating polyradiculoneuropathy associated with systemic lupus erythematosus. 61
33383292 2021
2
The dilemma of diabetes in chronic inflammatory demyelinating polyneuropathy. 61
27389526 2016
3
[Autoimmune neuropathies--current aspects of immunopathologic diagnostics and therapy]. 61
16080020 2005
4
T-cell cytotoxicity of human Schwann cells: TNFalpha promotes fasL-mediated apoptosis and IFN gamma perforin-mediated lysis. 61
12838506 2003
5
Chemokines and chemokine receptors in inflammatory demyelinating neuropathies: a central role for IP-10. 61
11912115 2002
6
Bradykinin B1 receptor expression and function on T lymphocytes in active multiple sclerosis. 61
10599786 1999
7
[Chronic inflammatory demyelinating polyneuritis]. 61
1340887 1992

Variations for Chronic Inflammatory Demyelinating Polyneuritis

Expression for Chronic Inflammatory Demyelinating Polyneuritis

Search GEO for disease gene expression data for Chronic Inflammatory Demyelinating Polyneuritis.

Pathways for Chronic Inflammatory Demyelinating Polyneuritis

Pathways related to Chronic Inflammatory Demyelinating Polyneuritis according to GeneCards Suite gene sharing:

(show all 29)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.47 TNF MPL IL9 IL18R1 IL17F IFNG
2
Show member pathways
13.32 TNF IL9 IL18R1 FASLG CD2 CCL4L1
3
Show member pathways
13.27 TNF IL9 IL18R1 IL17F IFNG FASLG
4
Show member pathways
13.2 TNF IL9 IL18R1 FASLG CD2 CCL4L1
5
Show member pathways
12.65 TNF PRF1 IL9 IFNG FASLG CD8A
6
Show member pathways
12.42 TNF PRF1 IFNG FASLG
7 12.4 TNF MPL IFNG FASLG CD8A CD2
8
Show member pathways
12.24 TNF IL17F IFNG CCL11
9
Show member pathways
12.23 TNF IL18R1 CCL4L1 CCL11
10
Show member pathways
12.09 TNF IFNG FASLG CCL11
11 11.85 TNF IL17F FASLG CCL11
12 11.81 TNF CD8A CD2
13
Show member pathways
11.77 IL18R1 IFNG FASLG CD8A CCL4L1
14
Show member pathways
11.68 TNF IL18R1 IFNG
15
Show member pathways
11.68 TNF IFNG FASLG
16 11.66 TNF IFNG CD8A
17 11.47 TNF IFNG FASLG
18 11.46 TNF KLRB1 IL9 IFNG CD8A
19 11.45 TNF KLRB1 IFNG
20 11.4 IL9 IFNG CCL11
21 11.38 TNF IFNG FASLG
22
Show member pathways
11.27 TNF IFNG FASLG
23 11.19 TNF IL9 IFNG
24 11.16 TNF MPL KLRB1 IFNG CD8A CD2
25
Show member pathways
11.14 TNF PRF1 IFNG FASLG CD8A
26 11.13 TNF KNG1 IFNG FASLG
27
Show member pathways
11.12 PRF1 IL18R1 IFNG
28 11.08 PRF1 IL18R1 IFNG
29 10.9 TNF IL9 FASLG CD2 CCL4L1 CCL11

GO Terms for Chronic Inflammatory Demyelinating Polyneuritis

Cellular components related to Chronic Inflammatory Demyelinating Polyneuritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.76 TNF KNG1 IL9 IL17F IFNG FASLG
2 cell surface GO:0009986 9.43 TRPV4 TNF MPL FUT4 FASLG CD2
3 Gemini of coiled bodies GO:0097504 9.32 SMN2 SMN1
4 extracellular region GO:0005576 9.32 TNF PRF1 KNG1 IL9 IL17F IFNG
5 SMN complex GO:0032797 9.26 SMN2 SMN1

Biological processes related to Chronic Inflammatory Demyelinating Polyneuritis according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.83 TRPV4 TNF CCL4L1 CCL11
2 cytokine-mediated signaling pathway GO:0019221 9.77 TNF MPL IL17F FASLG CCL11
3 cellular response to interferon-gamma GO:0071346 9.74 FASLG CCL4L1 CCL11
4 positive regulation of inflammatory response GO:0050729 9.73 TRPV4 TNF IFNG
5 positive regulation of interferon-gamma production GO:0032729 9.67 TNF IL18R1 CD2
6 extrinsic apoptotic signaling pathway GO:0097191 9.61 TNF IFNG FASLG
7 negative regulation of amyloid-beta clearance GO:1900222 9.55 TNF IFNG
8 DNA-templated transcription, termination GO:0006353 9.54 SMN2 SMN1
9 necroptotic signaling pathway GO:0097527 9.51 TNF FASLG
10 immune response GO:0006955 9.5 TNF IL9 IL18R1 IFNG FASLG CD8A
11 positive regulation of killing of cells of other organism GO:0051712 9.48 PRF1 IFNG
12 positive regulation of chemokine (C-X-C motif) ligand 1 production GO:2000340 9.46 TRPV4 IL17F
13 positive regulation of interleukin-6 production GO:0032755 9.46 TRPV4 TNF IL17F IFNG
14 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.4 TNF IFNG
15 positive regulation of vitamin D biosynthetic process GO:0060557 9.32 TNF IFNG
16 positive regulation of nitrogen compound metabolic process GO:0051173 9.26 TNF IFNG
17 inflammatory response GO:0006954 9.17 TNF KNG1 IL9 IL18R1 IL17F CCL4L1

Molecular functions related to Chronic Inflammatory Demyelinating Polyneuritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.1 TNF IL9 IL17F IFNG FASLG CCL11

Sources for Chronic Inflammatory Demyelinating Polyneuritis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....